Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

BACKGROUND: There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as they are generally excluded from clinical trials due to risk of exacerbations. METHODS: This multicenter retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez Chanza, Nieves, Xie, Wanling, Issa, Majd, Dzimitrowicz, Hannah, Tripathi, Abhishek, Beuselinck, Benoit, Lam, Elaine, Zakharia, Yousef, Mckay, Rana, Shah, Sumit, Mortazavi, Amir, R. Harrison, Michael, Sideris, Spyridon, Kaymakcalan, Marina D, Abou Alaiwi, Sarah, Nassar, Amin H, Nuzzo, Pier Vitale, Hamid, Anis, K Choueiri, Toni, C Harshman, Lauren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174076/
https://www.ncbi.nlm.nih.gov/pubmed/32217762
http://dx.doi.org/10.1136/jitc-2020-000538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174076/
https://www.ncbi.nlm.nih.gov/pubmed/32217762
http://dx.doi.org/10.1136/jitc-2020-000538

Ejemplares similares